NSC-87877 inhibits DUSP26 function in neuroblastoma resulting in p53-mediated apoptosis

Cell Death and Disease

Volumn 6, Issue , 2015, Pages

  Shi, Y ^a   Ma, I T ^b   Patel, R H ^a   Shang, X ^a   Chen, Z ^a,a   Zhao, Y ^a   Cheng, J ^a   Fan, Y ^a   Rojas, Y ^a   Barbieri, E ^a   Yu, Y ^a   Jin, J ^a   Kim, E S ^c   Shohet, J M ^a   Vasudevan, S A ^a   Yang, J ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b MAYO CLINIC   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 3; CASPASE 7; DUAL SPECIFICITY PHOSPHATASE; DUAL SPECIFICITY PROTEIN PHOSPHATASE 26; HEAT SHOCK PROTEIN 27; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE P38; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NSC 87877; PROTEIN P53; PUMA PROTEIN; UNCLASSIFIED DRUG; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; DUSP26 PROTEIN, HUMAN; ENZYME INHIBITOR; HSPB1 PROTEIN, HUMAN; IMIDAZOLE DERIVATIVE; MAP-KINASE-ACTIVATED KINASE 2; MITOGEN ACTIVATED PROTEIN KINASE PHOSPHATASE; NSC-87877; PROTEIN SERINE THREONINE KINASE; PYRIDINE DERIVATIVE; QUINOLINE DERIVATIVE; SIGNAL PEPTIDE; SMALL INTERFERING RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL GROWTH; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FEMALE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NEUROBLASTOMA; NEUROBLASTOMA CELL; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR VOLUME; ANIMAL; ANTAGONISTS AND INHIBITORS; BRAIN NEOPLASMS; DRUG EFFECTS; DRUG SCREENING; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; HUMAN; KIDNEY; METABOLISM; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CASPASE 3; CELL LINE, TUMOR; DUAL-SPECIFICITY PHOSPHATASES; ENZYME INHIBITORS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HSP27 HEAT-SHOCK PROTEINS; HUMANS; IMIDAZOLES; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; KIDNEY; MICE; MICE, NUDE; MITOGEN-ACTIVATED PROTEIN KINASE PHOSPHATASES; NEUROBLASTOMA; P38 MITOGEN-ACTIVATED PROTEIN KINASES; POLY(ADP-RIBOSE) POLYMERASES; PROTEIN-SERINE-THREONINE KINASES; PYRIDINES; QUINOLINES; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84938779550     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2015.207     Document Type: Article

References (44)

1. Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 2003; 3: 203-216.
2. Park JR, Bagatell R, London WB, Maris JM, Cohn SL, Mattay KM et al. Children's Oncology Group's 2013 blueprint for research: neuroblastoma. Pediatr Blood Cancer 2012; 60: 985-993.
3. Tweddle DA, Pearson ADJ, Haber M, Norris MD, Xue C, Flemming C et al. The p53 pathway and its inactivation in neuroblastoma. Cancer Lett 2003; 197: 93-98.
4. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004; 303: 844-848.
5. Yuan Y, Liao Y-M, Hsueh C-T, Mirshahidi HR. Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP. J Hematol Oncol 2011; 4: 16.
6. Zawacka-Pankau J, Selivanova G. Pharmacological reactivation of p53 as a strategy to treat cancer. J Intern Med 2015; 277: 248-259.
7. Arvidsson Y, Hamazaki TS, Ichijo H, Funa K. ASK1 resistant neuroblastoma is deficient in activation of p38 kinase. Cell Death Differ 2001; 8: 1029-1037.
8. Filomeni G, Piccirillo S, Rotilio G, Ciriolo MR. p38MAPK and ERK1/2 dictate cell death/ survival response to different pro-oxidant stimuli via p53 and Nrf2 in neuroblastoma cells SH-SY5Y. Biochem Pharmacol 2012; 83: 1349-1357.
9. Gao B, Shi H-L, Li X, Qiu S-P, Wu H, Zhang B-B et al. p38 MAPK and ERK1/2 pathways are involved in the pro-apoptotic effect of notoginsenoside Ft1 on human neuroblastoma SH-SY5Y cells. Life Sci 2014; 108: 63-70.
10. Osone S, Hosoi H, Kuwahara Y, Matsumoto Y, Iehara T, Sugimoto T. Fenretinide induces sustained-activation of JNK/p38 MAPK and apoptosis in a reactive oxygen speciesdependent manner in neuroblastoma cells. Int J Cancer 2004; 112: 219-224.
11. Battaglia-Hsu S-F, Akchiche N, Noel N, Alberto J-M, Jeannesson E, Orozco-Barrios CE et al. Vitamin B12 deficiency reduces proliferation and promotes differentiation of neuroblastoma cells and up-regulates PP2A, proNGF, and TACE. Proc Natl Acad Sci USA 2009; 106: 21930-21935.
12. Janssens V, Rebollo A. The role and therapeutic potential of Ser/Thr phosphatase PP2A in apoptotic signalling networks in human cancer cells. Curr Mol Med 2012; 12: 268-287.
13. Meehan M, Parthasarathi L, Moran N, Jefferies CA, Foley N, Lazzari E et al. Protein tyrosine phosphatase receptor delta acts as a neuroblastoma tumor suppressor by destabilizing the aurora kinase a oncogene. Mol Cancer 2012; 11: 6.
14. Nguyn LB, Diskin SJ, Capasso M, Wang K, Diamond MA, Glessner J et al. Phenotype restricted genome-wide association study using a gene-centric approach identifies three low-risk neuroblastoma susceptibility loci. PLoS Genet 2011; 7: e1002026.
15. Bulavin DV, Demidov ON, Saito S, Kauraniemi P, Phillips C, Amundson SA et al. Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity. Nat Genet 2002; 31: 210-215.
16. Li J, Yang Y, Peng Y, Austin RJ, van Eyndhoven WG, Nguyen KCQ et al. Oncogenic properties of PPM1D located within a breast cancer amplification epicenter at 17q23. Nat Genet 2002; 31: 133-134.
17. Richter M, Dayaram T, Gilmartin AG, Ganji G, Pemmasani SK, Van Der Key H et al. WIP1 phosphatase as a potential therapeutic target in neuroblastoma. PLoS One 2015; 10: e0115635.
18. Vasudevan SA, Skoko J, Wang K, Burlingame SM, Patel PN, Lazo JS et al. MKP-8, a novel MAPK phosphatase that inhibits p38 kinase. Biochem Biophys Res Commun 2005; 330: 511-518.
19. Takagaki K, Shima H, Tanuma N, Nomura M, Satoh T, Watanabe M et al. Characterization of a novel low-molecular-mass dual specificity phosphatase-4 (LDP-4) expressed in brain. Mol Cell Biochem 2006; 296: 177-184.
20. Song M, Park JE, Park SG, Do Hee Lee, Choi H-K, Park BC et al. NSC-87877, inhibitor of SHP-1/2 PTPs, inhibits dual-specificity phosphatase 26 (DUSP26). Biochem Biophys Res Commun 2009; 381: 491-495.
21. Yu W, Imoto I, Inoue J, Onda M, Emi M, Inazawa J. A novel amplification target, DUSP26, promotes anaplastic thyroid cancer cell growth by inhibiting p38 MAPK activity. Oncogene 2006; 26: 1178-1187.
22. Shang X, Vasudevan SA, Yu Y, Ge N, Ludwig AD, Wesson CL et al. Dual-specificity phosphatase 26 is a novel p53 phosphatase and inhibits p53 tumor suppressor functions in human neuroblastoma. Oncogene 2010; 29: 4938-4946.
23. Guadamillas MC, Cerezo A, Del Pozo MA. Overcoming anoikis-pathways to anchorageindependent growth in cancer. J Cell Sci 2011; 124(Pt 19): 3189-3197.
24. Honorat JF. SHP1 tyrosine phosphatase negatively regulates NPM-ALK tyrosine kinase signaling. Blood 2006; 107: 4130-4138.
25. Oda K. p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53. Cell 2000; 102: 849-862.
26. Takekawa M, Adachi M, Nakahata A, Nakayama I, Itoh F, Tsukuda H et al. p53-inducible wip1 phosphatase mediates a negative feedback regulation of p38 MAPK-p53 signaling in response to UV radiation. EMBO J 2000; 19: 6517-6526.
27. Nakamura Y, Ozaki T, Niizuma H, Ohira M, Kamijo T, Nakagawara A. Functional characterization of a new p53 mutant generated by homozygous deletion in a neuroblastoma cell line. Biochem Biophys Res Commun 2007; 354: 892-898.
28. Van Maerken T, Rihani A, Dreidax D, De Clercq S, Yigit N, Marine J-C et al. Functional analysis of the p53 pathway in neuroblastoma cells using the small-molecule MDM2 antagonist nutlin-3. Mol Cancer Ther 2011; 10: 983-993.
29. Kumar S, Jiang MS, Adams JL, Lee JC. Pyridinylimidazole compound SB 203580 inhibits the activity but not the activation of p38 mitogen-activated protein kinase. Biochem Biophys Res Commun 1999; 263: 825-831.
30. Patterson DM, Shohet JM, Kim ES. Preclinical models of pediatric solid tumors (neuroblastoma) and their use in drug discovery. Curr Protoc Pharmacol 2011; Chapter 14: 14.17-14.17.18.
31. Nikolaev AY, Li M, Puskas N, Qin J, Gu W. Parc: a cytoplasmic anchor for p53. Cell 2003; 112: 29-40.
32. Slack AD, Chen Z, Ludwig AD, Hicks J, Shohet JM. MYCN-directed centrosome amplification requires MDM2-mediated suppression of p53 activity in neuroblastoma cells. Cancer Res 2007; 67: 2448-2455.
33. Barbieri E, Mehta P, Chen Z, Zhang L, Slack A, Berg S et al. MDM2 inhibition sensitizes neuroblastoma to chemotherapy-induced apoptotic cell death. Mol Cancer Ther 2006; 5: 2358-2365.
34. Höpker K, Hagmann H, Khurshid S, Chen S, Schermer B, Benzing T et al. Putting the brakes on p53-driven apoptosis. Cell Cycle 2012; 11: 4122-4128.
35. Han J, Sun P. The pathways to tumor suppression via route p38. Trends Biochem Sci 2007; 32: 364-371.
36. Bulavin DV, Saito S, Hollander MC, Sakaguchi K, Anderson CW, Appella E et al. Phosphorylation of human p53 by p38 kinase coordinates N-terminal phosphorylation and apoptosis in response to UV radiation. EMBO J 1999; 18: 6845-6854.
37. Thornton TM, Pedraza-Alva G, Deng B, Wood CD, Aronshtam A, Clements JL et al. Phosphorylation by p38 MAPK as an alternative pathway for GSK3 inactivation. Science 2008; 320: 667-670.
38. Hershko T, Korotayev K, Polager S, Ginsberg D. E2F1 modulates p38 MAPK phosphorylation via transcriptional regulation of ASK1 and Wip1. J Biol Chem 2006; 281: 31309-31316.
39. Patterson KI, Brummer T, Daly RJ, O'Brien PM. DUSP26 negatively affects the proliferation of epithelial cells, an effect not mediated by dephosphorylation of MAPKs. Mol Cell Res 2010; 1803: 1003-1012.
40. Kim H, Lee H-J, Oh Y, Choi S-G, Hong S-H, Kim H-J et al. The DUSP26 phosphatase activator adenylate kinase 2 regulates FADD phosphorylation and cell growth. Nat Commun 2014; 5: 1-11.
41. Burmakin M, Shi Y, Hedström E, Kogner P, Selivanova G. Dual targeting of wild-type and mutant p53 by small molecule RITA results in the inhibition of N-Myc and key survival oncogenes and kills neuroblastoma cells in vivo and in vitro. Clin Cancer Res 2013; 19: 5092-5103.
42. Fan Y-H, Cheng J, Vasudevan SA, Dou J, Zhang H, Patel RH et al. USP7 inhibitor P22077 inhibits neuroblastoma growth via inducing p53-mediated apoptosis. Cell Death Dis 2013; 4: e867-10.
43. Cheng J, Fan Y-H, Xu X, Zhang H, Dou J, Tang Y et al. A small-molecule inhibitor of UBE2N induces neuroblastoma cell death via activation of p53 and JNK pathways. Cell Death Dis 2014; 5: e1079-12.
44. Budanov AV, Sablina AA, Feinstein E, Koonin EV, Chumakov PM. Regeneration of peroxiredoxins by p53-regulated sestrins, homologs of bacterial AhpD. Science 2004; 304: 596-600.